CA19-9在胰腺癌中的应用价值及局限性

陈达; 樊艳华

CA19-9在胰腺癌中的应用价值及局限性

陈达,
樊艳华

中日友好医院消化内科

基金项目:

中日友好医院院级科研基金(2010-MS-05)；

详细信息

中图分类号: R735.9
计量
- 文章访问数: 3581
- HTML全文浏览量: 26
- PDF下载量: 824
- 被引次数: 0
出版历程
- 出版日期: 2013-03-20

Clinical value and limitations of serum CA19-9 as a biomarker of pancreatic cancer

Chen Da,
Fan YanHua

Research funding:

摘要

摘要:
胰腺癌的诊治是世界性难题,糖类抗原CA19-9对于胰腺癌的诊断、疗效观察及预后判断等方面具有一定的临床价值,与其他肿瘤标志物比较,具有较好的敏感性及特异性,是最常用的胰腺癌的标志物。但其也存在诸多的局限性,尤其是具有较高的假阳性率及在Lewis a阴性基因型患者中的假阴性,极大限制了其作为胰腺癌诊断标准的应用。因此,血清CA19-9水平的升高需结合影像学及组织学证据,才能做出正确判断。
- 胰腺肿瘤 /
- 抗原,肿瘤相关,碳水化合物
Abstract:
Timely diagnosis and effective treatment of pancreatic cancer remains a distinct clinical challenge.Serum carbohydrate antigen (CA19-9) has emerged as a promising biomarker of pancreatic tumors and clinical studies have indicated its potential benefit in diagnosis, prognosis, and management of the disease.Compared with other biomarkers, serum CA19-9 shows better sensitivity and specificity for diagnosis of pancreatic cancer, but many limitations exist.Besides general instances of false-positive results, serum CA19-9 is associated with a high rate of false-negative results for patients with the Lewis-negative phenotype.Therefore, while serum CA19-9 may be a clinically valuable biomarker of pancreatic cancer, its results should be confirmed with imaging and histological findings.
- pancreatic neoplasms /
- antigens

HTML全文

参考文献(21)

[1]Jemal A, Siegel R, Ward E, et al.Cancer statieties, 2009[J].CA Cancer J Clin, 2009, 59 (4) :225-249.

[2]Steinberg W.The clinical utility of the CA 19-9 tumor associate anti-gen[J].Am J Gastroenterol, 1990, 85 (4) :350-355.

[3]Goonelilleke KS, Siriwardena AK.Systematic review of carbohy-drate antigen (CA 19-9) as a biochemical marker in the diagnosisof pancreatic cancer[J].Eur J Surg Oncol, 2007, 33 (3) :266-270.

[4]Ballehaninna UK, Chamberlain RS.The clinical utility of serumCA19-9 in the diagnosis, prognosis and management of pancreaticadenocarcinoma:An evidence based appraisal[J].J GastrointestOncol, 2012, 3 (2) :105-118.

[5]黄美君, 罗遐杰, 潘新亮, 等.CA199对胰腺癌的诊断价值[J].现代实用医学, 2007, 19 (12) :963-970.

[6]Wei ZY, Wang J, Yang YQ.The value of clinical expression of CAseries in malignancy diagnosis[J].J Radioimmunol, 2002, 15 (2) :84-86. (in Chinese) 韦振元, 王洁, 杨永青.CA系列对恶性肿瘤诊断临床表达的价值[J].放射免疫学杂志, 2002, 15 (2) :84-86.

[7]Wu HL, Chen ZP, Deng Y, et al.Quality assessment of diagnosticstudies on using CA199 to diagnose pancreatic carcinoma[J].Chongqing Med J, 2012, 41 (1) :31-35. (in Chinese) 伍惠玲, 陈智平, 邓燕, 等.血清CA199诊断胰腺癌的文献质量评价[J].重庆医学, 2012, 41 (1) :31-35.

[8]陶鹏辉.血清CA199检测在胰腺癌诊断和治疗中的应用价值[J].国际检验医学杂志, 2009, 30 (9) :914-915.

[9]Zhang LZ, Zhao Z, Wu B.Assay and clinical significance of serumtumor markers in diagnosis of pancreatic carcinoma[J].Cancer ResClin, 2008, 20 (11) :754-756. (in Chinese) 张丽中, 赵智, 吴滨.胰腺癌患者血清肿瘤标志物的检测及其临床意义[J].肿瘤研究与临床, 2008, 20 (11) :754-756.

[10]Waraya M, Yamashita K, Katagiri H, et al.Preoperative serumCA19-9 and dissected peripancreatic tissue margin determiners oflong-term survival in pancreatie cancer[J].Ann Surg Oncol, 2009, 16 (5) :1231-1240.

[11]Humphris1 JL, Chang DK, Johns AL, et al.The prognostic andpredictive value of serum CA19.9 in pancreatic cancer[J].AnnOncol, 2012, 23 (7) :1713-1722.

[12]Wang Y, Wu X, Wang YM, et al.The changes of serum levels ofCA 19-9 before and after gamma knife-therapy in pancreatic car-cinoma patients and its clinical significance[J].Prac J Med&Pharm, 2011, 8 (5) :394-395. (in Chinese) 王宇, 武霞, 汪延明, 等.伽玛刀放疗前后胰腺癌患者血清CA19-9水平变化及临床意义[J].实用医药杂志, 2011, 8 (5) :394-395.

[13]Lamerz R.Role of tumor markers, cytogenetics[J].Ann Oncol, 1999, 10 (Suppl 4) :145-149.

[14]Wang JH, Gao G, Li HR, et al.The clinical significance of serumlevel of CA19-9 in patients with common cluct stones[J].Chin JGastroenterol Hepatol, 2010, 19 (17) :659-660. (in Chinese) 齐国娟, 矫秀红, 王绍金, 等.CA199在良性胆道疾病中的意义[J].黑龙江医药科学, 2010, 33 (5) :109.

[15]王继恒, 高革, 李浩然, 等.血清CA19-9水平在胆总管结石中的临床意义[J].胃肠病学和肝病学杂志, 2010, 19 (7) :659-660.

[16] Kim JE, Lee KT, Lee JK, et al.Clinical usefulness of carbohydrateantigen 19-9 as a screening test for pancreatic cancer in an asymp-tomatic population[J].J Gastroenterol Hepatol, 2004, 19 (2) :182-186.

[17]Chang CY, Huang SP, Chiu HM, et al.Low efficacy of serum lev-els of CA 19-9 in prediction of malignant diseases in asymptomat icpopulat ion in Taiwan[J].Hepatogast roenterology, 2006, 53 (67) :1-4.

[18]Takasaki H, Uchida E, Tempero MA, et al.Correlative study onexpression of CA19-9 and DU-Pan-2 in tumor tissue and in ser-um of pancreatic cancer patients[J].Cancer Res, 1988, 48 (6) :1435-1438.

[19]Safi F, Schlosser W, Falkenreck S, et al.CA 19-9 serum courseand prognosis of pancreatic cancer[J].Int J Pancreatol, 1996, 20 (3) :155-161.

[20]Wu AZ, Liang Z, Wang HF.Analysis of serum CA199, CA242, CA125, CEA of pancreatic cancer patient[J].Chin J Lab Diagn, 2011, 15 (7) :1087-1088. (in Chinese) 吴爱祝, 梁茱, 王海枫.胰腺癌患者血清中CA199、CA242、CA125、CEA检测分析[J].中国实验诊断学, 2011, 15 (7) :1087-1088.

[21]Li N, Shen SQ, Liu JC.Values of CA19-9, CA242, CEA, andCA125 in diagnosis and prognosis for pancreatic cancer[J].Chin JBases Clin General Surg, 2011, 18 (3) :300-304. (in Chinese) 李宁, 沈世强, 刘建超.血清CA19-9、CA242、CEA及CA125在胰腺癌诊断和预后中的价值[J].中国普外基础与临床杂志, 2011, 18 (3) :300-304.

施引文献

资源附件(0)

访问统计